Track: Triple Negative Breast Cancer (TNBC)

The session on Triple-Negative Breast Cancer (TNBC) focuses on this challenging disease, which lacks expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, necessitating complex and aggressive treatment strategies.

Molecular Heterogeneity - Recent research has moved beyond the simple 'triple-negative' label to categorize TNBC into distinct subtypes based on gene expression profiles. Understanding this heterogeneity is critical for moving beyond generalized chemotherapy and designing truly personalized therapeutic approaches.

A major breakthrough is the Integrating Immune Checkpoint Inhibitors (ICIs) in Neoadjuvant/Adjuvant Settings. TNBC is often highly immunogenic. Speakers will review pivotal trial data establishing the use of anti-PD-L1 agents with chemotherapy, demonstrating how increasing the pathological complete response (pCR) rate in the neoadjuvant setting significantly improves long-term survival.

The session will delve into strategies exploiting specific tumor vulnerabilities, particularly Exploiting DNA Repair Deficiencies with PARP Inhibitors. Given that a significant fraction of TNBC exhibits homologous recombination deficiency (HRD), often due to BRCA1/2 mutations, PARP inhibitors are a key targeted strategy. Presentations will cover patient selection via germline and somatic testing and clinical data supporting their use in both early and advanced stages to prevent recurrence.

Role of Antibody-Drug Conjugates (ADCs), such as Sacituzumab Govitecan, which links a potent chemotherapeutic agent to an antibody targeting a protein highly expressed on TNBC cells (TROP2). This has provided a vital new treatment option for refractory metastatic disease.

Furthermore, we will discuss Optimizing Chemotherapy Regimens and Dose-Dense Strategies, refining the established cytotoxic backbone of treatment. Practical considerations for Management of Residual Disease After Neoadjuvant Therapy are critical, focusing on strategies like post-neoadjuvant capecitabine, which provides an opportunity to prevent relapse in patients who do not achieve a pCR. Finally, given the propensity of TNBC to metastasize to the brain, we will explore targeted approaches for Addressing Brain Metastases in TNBC, balancing local therapy (radiation) with systemic agents that penetrate the blood-brain barrier.

4th International Conference on Cancer and Breast Cancer Treatment

Track: Triple Negative Breast Cancer (TNBC)

Scientific Highlights

Organization Location

Mail us at

Our Social Presence

Call us at